Other analysts have also issued reports about the stock. Canaccord Genuity restated a buy rating and set a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Seaport Global Securities restated a buy rating on shares of Aldeyra Therapeutics in a research report on Thursday, March 1st. Cantor Fitzgerald set a $23.00 price target on Aldeyra Therapeutics and gave the stock a buy rating in a report on Thursday, March 29th. ValuEngine raised Aldeyra Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Zacks Investment Research cut Aldeyra Therapeutics from a hold rating to a sell rating in a research report on Wednesday, April 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Aldeyra Therapeutics currently has a consensus rating of Buy and a consensus price target of $16.93.
Shares of NASDAQ ALDX opened at $7.05 on Monday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $11.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.12 and a current ratio of 13.12.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after acquiring an additional 9,407 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Aldeyra Therapeutics during the third quarter valued at $134,000. 683 Capital Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 59.1% during the third quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock valued at $6,016,000 after purchasing an additional 310,421 shares during the last quarter. Woodstock Corp raised its position in Aldeyra Therapeutics by 20.4% during the fourth quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 9,850 shares during the period. Finally, Geode Capital Management LLC raised its position in Aldeyra Therapeutics by 34.6% during the fourth quarter. Geode Capital Management LLC now owns 102,263 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 26,269 shares during the period. Hedge funds and other institutional investors own 49.74% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.